Morphotek Series D Raises $40M For Antibody Headway

Available cash will take the firm "well into 2009," said Nicholas Nicolaides, president, CEO and co-founder of Exton, Pa.-based Morphotek. By then, full Phase II data should be available for the two most advanced antibodies, with the lead compound in a Phase III pivotal trial, he said. (BioWorld Today)